arrow
T

Tessa Niemeyer-van der Kolk

centre for human drug research
H指数:11
被引数:426

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lack of improvement after short-term topical antistaphylococcal endolysin SA.100 therapy in patients with mild-to-moderate atopic dermatitis: Results from a randomized, vehicle-controlled trial

短期局部抗金黄色葡萄球菌内溶素SA.100治疗后轻中度特应性皮炎患者缺乏改善:来自一项随机、安慰剂对照试验的结果

2026-05-110
OAAI
Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation
2026-02-060
OAAI
Mild psoriasis as a suitable model for proof-of-mechanism in a phase 1B setting: Results from a double-blind placebo-controlled trial with guselkumab

中重度银屑病作为机制验证的合适模型:一项关于guselkumab的双盲、安慰剂对照试验结果

2025-07-280
OAAI
Similar Alterations of the Stratum Corneum Ceramide Profile in Atopic Dermatitis, Psoriasis, and Ichthyosis: Results from a Systematic Review and Meta-Analysis

特应性皮炎、银屑病和鱼鳞病患者角质层神经酰胺谱的相似改变: 一项系统回顾和荟萃分析的结果

2024-10-011
OAAI
Guselkumab induction therapy demonstrates long-lasting efficacy in patients with mild psoriasis, results from a randomized, placebocontrolled exploratory clinical trial
2024-02-011
OAAI
Lesional skin of seborrheic dermatitis patients is characterized by skin barrier dysfunction and correlating alterations in the stratum corneum ceramide composition
2023-11-1611
OAAI
Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial
2022-04-0124
OAAI
Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo-Controlled, Phase II Trial
2020-05-0131
OAAI